We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics

Download Mobile App

Unique Antibody Test Screens for COVID-19 Vaccine-Induced Blood Clots

By LabMedica International staff writers
Posted on 07 May 2021
Print article
Image: Unique Antibody Test Screens for COVID-19 Vaccine-Induced Blood Clots (Photo courtesy of Versiti, Inc.)
Image: Unique Antibody Test Screens for COVID-19 Vaccine-Induced Blood Clots (Photo courtesy of Versiti, Inc.)
A unique offering of new testing options aims to aid physicians in managing suspected blood clots following the administration of adenovirus-based COVID-19 vaccines.

Versiti, Inc. (Milwaukee, WI, USA) has unveiled the first comprehensive diagnostic testing menu for suspected vaccine-induced immune thrombotic-thrombocytopenia (VITT) in the US. Cases of patients developing clots (thrombosis) with low platelet counts (thrombocytopenia) have been reported following administration of adenovirus-based COVID-19 vaccines. VITT is considered to be a rare side effect of the adenovirus vector-based vaccines for COVID-19. Per reports in the medical literature, cases of VITT have been reported between 3 and approximately 20 days post vaccination.

Versiti’s unique test offering determines the presence and function of platelet-activating antibodies in patients’ blood. Published communications in the medical literature have identified the presence of these antibodies as being a key finding following the development of these life-threatening clots in individuals receiving specific COVID vaccines. These antibodies are similar to those seen in Heparin Induced Thrombocytopenia (HIT). Once a patient has these antibodies, physicians and providers must implement alternate anticoagulation therapies to care for the individual.

“Accurate assessment of VITT is critical to guiding appropriate drug selection and management of patients with blood clot side effects,” said Dr. Ruchika Sharma, associate medical director of Versiti’s platelet immunology laboratory. “Patients receiving incorrect therapies could be at risk for serious bleeding complications or, in some cases, worsening of their existing blood clot(s). This testing menu leverages Versiti’s decades of experience in immune platelet disorders, to provide physicians with the necessary tools to aid in the care and management of patients with suspected VITT.”

Related Links:
Versiti, Inc.

Gold Supplier
COVID-19 Neutralization Antibody Test
iFlash-2019-nCoV Neutralization Antibody Test
Fume Adsorber
Fume Adsorber-2
Influenza A/B Assay
Influenza A+B One Step Assay
COVID-19 Detection Kits
PCR Diagnostic Solution

Print article
BIOHIT  Healthcare OY


Clinical Chem.

view channel
Image: Blood test for  plasma aldosterone concentration was used to screen For hyperaldosteronism in hypertensive men (Photo courtesy of  VisitHealth Ltd)

Urinary Sodium/Potassium Ratio Screens for Hyperaldosteronism in Hypertensive Men

Among individuals with hypertension, the prevalence of secondary hypertension has been reported to be around 10%. More than half of individuals with secondary hypertension have associated hyperaldosteronism.... Read more


view channel

Global Clinical Chemistry Analyzers Market to Reach USD 15.97 Billion by 2028

The global clinical chemistry analyzers market is projected to grow at a CAGR of 4.25% from USD 11.45 billion in 2020 to USD 15.97 billion by 2028, driven by growth in technology, rising global population,... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.